Not Better Late Than Never: Timing Requirement is Material to Payment
Client Alert | 1 min read | 06.15.18
On June 11, 2018, in U.S. ex rel Prather v. Brookdale Senior Living Communities Inc., the Sixth Circuit reversed dismissal of a False Claims Act suit against the country’s largest senior living provider because the relator had sufficiently alleged materiality. The qui tam suit was brought by a former nurse who alleged that physician certifications of patient need for home-health care were not signed until months after the care had been provided, in violation of 42 C.F.R. § 424.22 which requires that such certifications be completed at the time a plan of care is established or “as soon thereafter as possible.”
Applying the factors that the Supreme Court identified in its Escobar decision, the Sixth Circuit held in a 2-1 decision that the relator sufficiently pleaded that the timing requirement in § 424.22 was material by alleging that it was an express condition of payment and referring to guidance documents suggesting that compliance with the timing requirement went to the “essence of the bargain” between the defendants and the government. Notably, the lower court had drawn a negative inference on materiality because the complaint contained no allegations about the government’s past practice vis-à-vis claims that did not comply with the timing requirement in § 424.22. The Sixth Circuit found that this was “one step too far” because although past government actions are relevant to the materiality analysis, they are not dispositive.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection



